{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.92","upperLimit":"3.67","value":"1.87"},{"groupId":"OG001","lowerLimit":"1.64","upperLimit":"3.44","value":"2.07"},{"groupId":"OG002","lowerLimit":"2.0","upperLimit":"7.6","value":"3.6"},{"groupId":"OG003","lowerLimit":"1.2","upperLimit":"1.8","value":"1.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"20"}],"units":"Participants"}],"description":"The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. Cohort A (liposarcoma) and Cohort B (osteosarcoma). PFS will be evaluated according to RECIST (Response Evaluation Criteria In Solid Tumors) 1.1, where a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off\n\nRegorafenib\n\nRegorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off","id":"OG000","title":"Cohort A: Liposarcoma"},{"description":"21 days on and 7 days off\n\nPlacebo\n\nPlacebo: 21 days on and 7 days off","id":"OG001","title":"Cohort A: Liposarcoma, Placebo"},{"description":"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off\n\nRegorafenib\n\nRegorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off","id":"OG002","title":"Cohort B: Osteosarcoma"},{"description":"21 days on and 7 days off\n\nPlacebo\n\nPlacebo: 21 days on and 7 days off","id":"OG003","title":"Cohort B: Osteosarcoma, Placebo"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"up to 3 years","title":"Progression-free Survival (PFS). Cohort A and Cohort B","type":"PRIMARY","unitOfMeasure":"months"}